title: Release of platelet plasminogen activator inhibitor 1 in whole blood is increased in patients with type II diabetes.
abstract: OBJECTIVE
  To compare platelet plasminogen activator inhibitor 1 (PAI-1) release in type II diabetic patients and healthy control subjects.
  
  
  METHODS
  We studied a group of 27 diabetic patients and a group of 16 nondiabetic control subjects. Whole-blood platelet aggregation, defined as a decrease in platelet count during shaking (180 rpm) of blood samples at 37 degrees C, and plasma PAI-1 antigen concentrations were measured in parallel at time 0, 7.5, 15, 30, 60, 120, and 180 min.
  
  
  RESULTS
  Platelet aggregation did not differ significantly between the two groups at any time period. However, the increase in plasma PAI-1 antigen concentration over basal levels at time 0 was higher for the group of diabetic patients when compared with their matched control subjects. The increment of PAI-1 antigen was 61.8 +/- 29.4 vs. 35.9 +/- 13.4 ng/ml (P < 0.005, means +/- SD) after 180 min for the diabetic and control subjects, respectively. Platelet PAI-1 release was correlated to very-low-density lipoprotein cholesterol and triglyceride plasma levels, but not to HbA1c levels.
  
  
  CONCLUSIONS
  Platelets of patients with type II diabetes release significantly more PAI-1 than platelets of healthy subjects at the same level of platelet aggregation. This may contribute to enhanced thrombosis in diabetes.
authors.affiliation: Ralph H. Johnson Department of Veterans Affairs Medical Center, Charleston, South Carolina 29401, USA.
authors.forename: R
authors.initials: R
authors.lastname: Jokl
authors.forename: R L
authors.initials: RL
authors.lastname: Klein
authors.forename: M F
authors.initials: MF
authors.lastname: Lopes-Virella
authors.forename: J A
authors.initials: JA
authors.lastname: Colwell
mesh_terms: D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D001792:Blood Platelets / Q000502:physiology*; D002096:C-Peptide / Q000097:blood; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D015243:Cholesterol, VLDL / Q000097:blood; D015331:Cohort Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood*; D003925:Diabetic Angiopathies / Q000097:blood; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D006973:Hypertension / Q000097:blood; D066298:In Vitro Techniques; D007328:Insulin / Q000097:blood; D008297:Male; D008875:Middle Aged; D017395:Plasminogen Activator Inhibitor 1 / Q000097:blood*; D015539:Platelet Activation; D010974:Platelet Aggregation; D012016:Reference Values; D014280:Triglycerides / Q000097:blood
chemical_list: D002096:C-Peptide; D002784:Cholesterol; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D015243:Cholesterol, VLDL; D006442:Glycated Hemoglobin; D007328:Insulin; D017395:Plasminogen Activator Inhibitor 1; D014280:Triglycerides